132 results on '"Atchison, Kevin"'
Search Results
2. Author Correction: Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease
3. Enhanced Clearance of Aβ in Brain by Sustaining the Plasmin Proteolysis Cascade
4. Synthesis and structure–activity relationship of a novel series of heterocyclic sulfonamide γ-secretase inhibitors
5. Abstract 1909: Pan-TGF-β inhibition with PD-1 blockade as a combination treatment strategy to augment anti-tumor immune response in hepatocellular carcinoma
6. Abstract 4451: Combination of local mRNA immunotherapy with systemic immune checkpoint blockade demonstrates anti-tumor activity across a diverse range of preclinical syngeneic tumor models
7. Studies on monobactams I. Synthesis and β-lactamase inhibitory activity of 4-substituted 3-[(N-methyl-1,2,3-triazol-4-yl)-methylene]-2-azetidinone-1-sulfonates
8. Age-dependent disruption in hippocampal theta oscillation in amyloid-β overproducing transgenic mice
9. Aminomethyl-Derived Beta Secretase (BACE1) Inhibitors: Engaging Gly230 without an Anilide Functionality
10. Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors
11. Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug–Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors
12. Discovery of a Series of Efficient, Centrally Efficacious BACE1 Inhibitors through Structure-Based Drug Design
13. Aminomethyl-Derived Beta Secretase (BACE1) Inhibitors: Engaging Gly230 without an Anilide Functionality.
14. ( S) -N-(5-Chlorothiophene-2-sulfonyl)-β,β-diethylalaninol a Notch-1-sparing γ-secretase inhibitor
15. P4-278: Clinical gamma-secretase inhibitors (GSIs) alter beta-amyloid 40/42 ratio in brain and show CSF beta-amyloid rebound in vivo
16. P4–291: Predicting in vivo BACE inhibitor efficacy: Are human iPS‐derived neurons superior?
17. P2-400: Chronic BACE1 inhibition reduces pre-existing parenchymal amyloid plaque load in the brain of a mouse model of Alzheimer's disease
18. P4-288: Effect of A673T mutation on APP processing by BACE1 and its significance for Alzheimer's disease therapeutic research
19. P2–379: Disconnect between brain and CSF drug exposure and beta‐amyloid levels following BACE inhibition
20. P1–109: Inhibition of BACE1 reduces beta‐amyloid 1–40 but not N‐terminal‐truncated beta‐amyloid
21. P4-277: Evaluation of beta-amyloid-lowering efficacy of a novel BACE1 inhibitor in multiple species
22. P2-394: Characterization of beta-amyloid 1-40 across species following treatment with beta-secretase inhibitors
23. Effects of the γ-secretase inhibitor semagacestat on hippocampal neuronal network oscillation
24. Discovery of a novel series of Notch-sparing γ-secretase inhibitors
25. Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor
26. Pharmacological Assessment of <i>γ</i>-Secretase Activity from Rodent and Human Brain
27. Metabolism-Directed Design of Oxetane-Containing Arylsulfonamide Derivatives as γ-Secretase Inhibitors
28. Quantitative Pharmacokinetic/Pharmacodynamic Analyses Suggest That the 129/SVE Mouse Is a Suitable Preclinical Pharmacology Model for Identifying Small-Molecule γ-Secretase Inhibitors
29. P3-220: Age-dependent disruption in hippocampal theta oscillation in APP/PS1 mice
30. P2-254: Acute inhibition of gamma secretase lowers abeta dimer levels in plaque-bearing PSAPP mice
31. ChemInform Abstract: Studies on Monobactams. Part 1. Synthesis and β-Lactamase Inhibitory Activity of 4-Substituted 3-[(N-Methyl-1,2,3-triazol-4-yl)methylene]-2-azetidinone-1-sulfonates.
32. Begacestat (GSI-953): A Novel, Selective Thiophene Sulfonamide Inhibitor of Amyloid Precursor Protein γ-Secretase for the Treatment of Alzheimer's Disease
33. 3D Timelapse Analysis of Muscle Satellite Cell Motility
34. P4-050: Dysregulation of brain ApoE and cholesterol metabolism in APP transgenic mice
35. Discovery of Begacestat, a Notch-1-Sparing γ-Secretase Inhibitor for the Treatment of Alzheimer’s Disease
36. Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
37. P2-302: GSI-953 is a potent APP-selective gamma-secretase inhibitor for the treatment of Alzheimer's disease
38. P2-337: Characterization of the affinity of GSI-953 for binding to gamma-secretase and comparison to benchmark gamma-secretase inhibitors
39. Discovery of a Series of Efficient,Centrally EfficaciousBACE1 Inhibitors through Structure-Based Drug Design.
40. P4-244: Discovery of a novel series of notch-sparing γ-secretase inhibitors
41. P4-085: The role of liver X receptor (LXR) agonists in modulating Aβ levels In vitro and In vivo
42. Acute γ-Secretase Inhibition Improves Contextual Fear Conditioning in the Tg2576 Mouse Model of Alzheimer's Disease
43. In Vitro and In Vivo Activities of Syn2190, a Novel β-Lactamase Inhibitor
44. Studies on Penam Sulfones. II. Synthesis and .BETA.-Lactamase Inhibitory Activity of 2.BETA.-Carboxamide Penicillanic Acid Sulfones.
45. Predicting in vivo BACE inhibitor efficacy: Are human iPS-derived neurons superior?
46. Effect of A673T mutation on APP processing by BACE1 and its significance for Alzheimer's disease therapeutic research
47. Clinical gamma-secretase inhibitors (GSIs) alter beta-amyloid 40/42 ratio in brain and show CSF beta-amyloid rebound in vivo
48. Evaluation of beta-amyloid-lowering efficacy of a novel BACE1 inhibitor in multiple species
49. Chronic BACE1 inhibition reduces pre-existing parenchymal amyloid plaque load in the brain of a mouse model of Alzheimer's disease
50. Characterization of beta-amyloid 1-40 across species following treatment with beta-secretase inhibitors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.